April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Overcoming the overexpression toxicity of gene replacement therapy for Bardet Biedl Syndrome type 1
Author Affiliations & Notes
  • Arlene V Drack
    Ophthalmology, Univ of Iowa Hospitals, Iowa City, IA
  • Sajag Bhattarai
    Ophthalmology, Univ of Iowa Hospitals, Iowa City, IA
  • Seongjin Seo
    Ophthalmology, Univ of Iowa Hospitals, Iowa City, IA
  • Edwin M Stone
    Ophthalmology, Univ of Iowa Hospitals, Iowa City, IA
  • Val Sheffield
    Ophthalmology, Univ of Iowa Hospitals, Iowa City, IA
  • Robert Mullins
    Ophthalmology, Univ of Iowa Hospitals, Iowa City, IA
  • Budd A Tucker
    Ophthalmology, Univ of Iowa Hospitals, Iowa City, IA
  • Footnotes
    Commercial Relationships Arlene Drack, None; Sajag Bhattarai, None; Seongjin Seo, None; Edwin Stone, None; Val Sheffield, None; Robert Mullins, None; Budd Tucker, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4378. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arlene V Drack, Sajag Bhattarai, Seongjin Seo, Edwin M Stone, Val Sheffield, Robert Mullins, Budd A Tucker; Overcoming the overexpression toxicity of gene replacement therapy for Bardet Biedl Syndrome type 1. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4378.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Our previous work showed that BBS1 overexpression results in severe retinal cytotoxicity in vivo (Seo et al., IOVS 2013,11;54(9):6118-32) . This study sought to determine whether regulating expression levels of BBS1 using cell-type specific promoters and reduced multiplicity of infection could mitigate cytotoxicity and slow disease progression.

Methods: Human wild type (WT) BBS1 was packaged in an AAV2 vector under control of the rho kinase promoter, and in a lentiviral (LV) vector under control of the CMV promoter. Subretinal injections of 1x107 to 1x109 viral genomes in 1 microliter total volume were delivered to right eyes and AAV-GFP to control left eyes of P30-P60 mice (either WT or Bbs1M390R/M390R knock-in). Retinal function was analyzed by electroretinography (ERG) and retinal structure by optical coherence tomography (OCT). For LV vectors, right eyes received subretinal injection at P2-4 with uninjected left eyes as controls. LV vector was also used to treat induced pluripotent stem cell (iPSC) derived photoreceptor precursor cells generated from Bbs1M390R/M390R mouse fibroblasts in vitro.

Results: Transduction of iPSC derived photoreceptor precursor cells with LV particles containing human BBS1 resulted in widespread death, a result not detected in cultures transduced with an equal MOI of control LV-GFP. In vivo, the ERG of WT mice (n=3) eyes treated with LV-BBS1 was reduced by 50% at P191 compared to untreated eyes and OCT revealed a nodular retinal reaction. Subretinal AAV2-BBS1 with rho kinase promoter did not cause toxicity in WT mice eyes (n=2). In affected animals (n=6) a recordable difference in ERG amplitudes was detected, with eyes receiving therapeutic vector having slightly higher ERG amplitudes than sham injected eyes at both 1 and 8 weeks after injection.

Conclusions: Modulating the expression level of WT BBS1 by using the weaker, cell-type specific promoter rho kinase, delivering smaller volumes of viral particles subretinally, and using lower viral titers per injection mitigates overexpression toxicity and demonstrates a detectable improvement in the ERG of Bbs1M390R/M390R mice. Disease-specific iPSCs may be used to test vectors for toxicity. These results are encouraging for future gene therapy in people with this most common type of BBS.

Keywords: 538 gene transfer/gene therapy • 696 retinal degenerations: hereditary • 721 stem cells  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×